You are here

Patient Reported Outcomes in Pulmonary Arterial Hypertension

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of a personally signed and dated informed consent

- Subjects aged >=18 who have documented PAH

- Speak English

- Subjects who provide written informed consent to participate in the study before being
screened for the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with non-PAH Pulmonary Hypertension

- Physical inability to complete the interview process

- Subjects who are currently enrolled in an experimental drug study

NCT01792622
Pfizer
Withdrawn
Patient Reported Outcomes in Pulmonary Arterial Hypertension

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Familial Persistent Pulmonary Hypertension
NCT01720524
All Genders
0+
Years
Multiple Sites
Pulmonary Arterial Hypertension, Pulmonary Hypertension
NCT01642407
All Genders
1+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT01897740
All Genders
10+
Years
Moscow,
Patient Reported Outcomes in Pulmonary Arterial Hypertension
Patient Reported Outcomes in Pulmonary Arterial Hypertension
Develop a brief, new, patient reported outcome instrument that is valid for use in clinical practice and clinical trials.
This study will use the Clinical Impact Method to develop a patient reported outcome for use in patients with pulmonary arterial hypertension Clinical personnel at the study sites will approach and discuss possible participation in Phase I and II of the study with subjects from the existing pool of patients currently receiving usual and customary care at the site.
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with pulmonary arterial hypertension
Pulmonary Arterial Hypertension
  • Other: Interview
    Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
  • Other: Questionnaire
    Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
  • Phase I Patient Interviews
    Indepth interviews will be completed with approximately 15 patients.
    Intervention: Other: Interview
  • Phase II Patient Questionnaire
    Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
    Intervention: Other: Questionnaire
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
September 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent
  • Subjects aged >=18 who have documented PAH
  • Speak English
  • Subjects who provide written informed consent to participate in the study before being screened for the study.

Exclusion Criteria:

  • Patients with non-PAH Pulmonary Hypertension
  • Physical inability to complete the interview process
  • Subjects who are currently enrolled in an experimental drug study
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01792622
A1481296
No
Not Provided
Not Provided
Pfizer
Pfizer
  • University of Chicago
  • Mayo Clinic
  • Vanderbilt University
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now